Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas - a review article

Polish Journal of Pathology

Volumn 59, Issue 3, 2008, Pages 121-127

  Jabłońska, Joanna ^a   Jesionek Kupnicka, Dorota ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ALGORITHM; CLASSIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; PROGNOSIS; REVIEW;

ALGORITHMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 59149104606     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. A predictive model for aggressive non - Hodgkin's lymphoma. The International Non - Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 1993, 329, 987-994.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al: Distinct types of diffuse large B - cell lym-phoma identified by gene expression profiling. Nature 2000, 403, 503-511.
3. Barrans SL, Carter I, Owen RG et al: Germinal center phenotype and bcl2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B - cell lymphoma. Blood 2003, 99, 1136-1143.
4. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlarson M et al: Evaluation of immunophenotype in diffuse large B - cell lymphoma and its impact on prognosis. Modern Pathology 2005, 18, 1113-1120.
5. Biasoli I, Morais JC, Scheliga A, Milito CB, Romano S, Land M et al: CD10 and Bcl2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large B - cell lymphoma with very good or very poor prognoses. Histopathology 2005, 46, 328-333.
6. Blay J, Gomez F, Sebban C et al: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998, 92, 3562-3568.
7. Chang CC, McClintock S, Cleveland RP et al: Immunohisto-chemical expression patterns of germinal center and activation B - cell markers correlate with prognosis in diffuse large B - cell lymphoma. Am J Surg Pathol 2004, 28, 464-470.
8. Colomo L, Lopez-Guillermo A, Perales M et al: Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B - cell lymphoma. Blood 2003, 101, 78-84.
9. De Leval, Harris NL: Variability in immunophenotype in diffuse large B - cell lymphoma and its clinical relevance. Histopathology 2003, 43, 509-528.
10. Fabiani B, Delmer A, Lepage E et al: Prognostic significance and morphological features of diffuse large B - cell lymphomas expressing CD10. J Clin Pathol 2002, 55S1, A14.
11. Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L: Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997, 8, 101-104.
12. Falini B, Fizzotti M, Pucciarini A et al: A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells and activated T cells. Blood 2000, 95, 2084-2092.
13. Farinha P, Sehn L, Skinnider B, Connors JM, Gascoyne RD: Addition of rituximab to CHOP improves survival in the non-GCB subtype of diffuse large B-cell lymphoma. Blood 2006, 108, 11, 816.
14. Gatter KC, Warnke RA: Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours, Pathology and Genetics. IARC Press: Lyon, 2001, 171-174.
15. Hans CP, Weisenburger DD, Greiner TC et al: Confirmation of the molecular classification of diffuse large B - cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103, 275-282.
16. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller - Hermelink HK, Vardiman J: Lymphoma classification - from controversy to consensus: the R.E.A.L. And WHO Classification of lymphoid neoplasms. Ann Oncol 2000, 11, 3-10.
17. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al: A revised European - American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84, 1361-1392.
18. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL et al: The t(14;18) defines a unique subset of diffuse large B - cell lymphoma with a ger-minal center B - cell gene expression profile. Blood 2002, 99, 2285-2290.
19. Hunt KE, Reichard KK: Diffuse large B-cell lymphoma. Arch Pathol Lab Med 2008, 132, 1, 118-124.
20. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A et al: BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006, 24, 961-968.
21. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dae B et al: Bcl2 translocation defines a unique tumor subset within the germinal center B - cell - like diffuse large B - cell lymphoma. Am J Pathol 2004, 165, 159-166.
22. Kaufmann O, Flath B, Spath-Schwalbe E, Possinger K, Dietel M: Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Am J Clin Pathol 1999, 111, 117-122.
23. Kramer M, Hermans J, Parker J et al: Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996, 14, 2131-2138.
24. Leroy K, Haioun C, Lepage E et al: P53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphoma. Ann Oncol 2002, 13, 1108-1115.
25. Monni O, Joenesuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S: BCL2 overexpression associated with chromosomal amplification in diffuse large B - cell lymphoma. Blood 1997, 90, 1168-1174.
26. Muris JJF, Meijer CJLM, Vos W, van Krieken JHJM, Jiwa NM et al: Immunohistochemical profiling based on Bcl - 2, CD10, and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B - cell lymphoma. J Pathol 2006, 208, 714-723.
27. National Cancer Institute sponsored study of classifications of non - Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non - Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1992, 49, 2112-2135.
28. Non - Hodgkin Lymphoma: an update, The Lancet, June 2004, Vol 5, 341-353.
29. Oshima K, Kawasaki C, Muta K et al: CD10 and Bcl10 expression in diffuse large B - cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001, 39, 156-162.
30. Pittaluga S, Ayoubi TA, Wlodarska I, Stul M, Cassiman JJ, Mecucci C et al: Bcl-6 expression in reactive lymphoid tissue and in B - cell non-Hodgkin's lymphomas. J Pathol 1996, 179, 145-150.
31. Rantanen S, Monni O, Joensuu H, Franssila K, Knuutila S: Causes and consequences of bcl2 overexpression in diffuse large B - cell lymphoma. Leukemia Lymphoma 2001, 42, 1089-1098.
32. Rosenwald A, Wright G, Chan WC et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large B - cell lymphoma. N Engl J Med. 2002, 346, 1937-1947.
33. Shaffer A, Yu X, He Y, Boldrick J, Chan E, Staudt L: Bcl-6 represses genes that function in lymphocyte differentiation, inflammation and cell cycle control. Immunity 2000, 13, 199-212.
34. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC et al: Diffuse large B - cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat Med 2002, 8, 1, 68-74.
35. Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD: Bcl-6 and Bcl-2 protein expression in diffuse large B - cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999, 30, 803-808.
36. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G et al: Updated Kiel classification for lymphomas. Lancet 1988, 1, 292-293.
37. Staudt LM: Ann Oncol 2005, 16 (Suppl 5): v36, abstract.
38. Tsuboi K, Iida S, Inagaki H et al: MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000, 14, 449-456.
39. Wilson W, Teruya-Feldstein J, Fest T: Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997, 89, 601-609.
40. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: A gene expression - based method to diagnose clinically distinct subgroups of diffuse large B - cell lymphoma. Proc Natl Acad Sci USA 2003, 100, 19, 10585-10587, 9991- 9996.
41. Zhang A, Ohshima K, Sato K et al: Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int 1999, 49, 1043-1052.